Lawrence Hughes Has a Video on YouTube

by jamiebowers 8 Replies latest watchtower medical

  • jamiebowers
  • Mickey mouse
    Mickey mouse

    Aresenic??!! WBTS administering ARSENIC?? I'd have to see more evidence of that.

    I find it very distracting that he repeatedly said "Jehovah Witnesses". I feel sorry for him if he lost his daughter to the WT blood polcy. The video could be better.

  • dawg

    Come on Mickey, he was nervous.

  • frankiespeakin

    I wish L H all the best and feel his loss.

    I think he needs to make some corrections in his facts ex: 100s of thousands of JWs have died because the blood policy

    Needs to rehearse it more to make it more flowing and fast moving would get more listeners.

  • Scully

    If I remember correctly, previous reports (including ones in the media) stated that Bethany Hughes had leukemia, not skin cancer, as he stated in the video.

  • Mickey mouse
    Mickey mouse

    Dawg, I'm not taking a cheap shot. I do feel for the man. I just feel the video could be more effective if revised. It's constructive criticism.

  • bob1999

    It could be that he does not believe the Jehovah's Witnesses are witnesses for Jehovah.

    So he does not want to call them something that they are not. He leaves the possessive off.


  • Wasanelder Once
    Wasanelder Once

    I thought he lost this lawsuit and the whole thing was over. Can someone update me on the current status or refer me to a thread where its discussed? I honestly thought he lost some months back. W.Once

  • Balsam

    The Arsenic treatment is an alternative one and we all know how much JW's love to latch on to alternative treatments because they don't trust the medical community.

    Arsenic Trioxide Questioned in Cancer Treatment Deaths
    Questions Are Raised About Drug Reaction
    Article date: 2001/08/01
    A drug called arsenic trioxide is thought to help patients with acute promyelocytic leukemia (APL) achieve remission, but three out of 10 patients taking the drug died suddenly during the first cycle of treatment during a clinical trial, according to a report in the July 15 th issue of Blood (Vol. 98, No. 2: 266-271).

    Peter Westervelt, MD, PhD, who recently became assistant professor at the University of Massachusetts Medical School in Worcester, and his colleagues from the Washington University School of Medicine in St. Louis, report that autopsies on two of the patients did not identify a cause of death, though bleeding into the lungs was reported in one, and they suspect that cardiac arrhythmia (irregularity of heartbeat) may have played a role in their deaths. The third patient’s heart stopped beating suddenly.

    The study was a phase I/II study in which Westervelt wanted to determine the greatest dose that people could take, the smallest dose that would achieve results, and any side effects associated with arsenic trioxide.

    Remission Was Short Lived

    Despite the deaths, six out of the seven remaining patients in the trial went into complete remission; however, the researchers note that the "durability of remissions in our series was short-lived in most cases, and no patients remained in remission without further therapy."

    According to the researchers, several studies have documented the efficacy of arsenic trioxide in treating patients with APL, including patients who have relapsed or who have not been helped by other treatments.

    "Hematological remission rates of 85% to 90% have been reported…with most patients eventually achieving cytogenetic or molecular remission without additional chemotherapy," the researchers write.

    Most studies also have reported no treatment-related deaths. But another recent study in the same journal documented a potentially fatal rapid heartbeat in three patients after treatment with arsenic trioxide, resulting in two deaths . All these patients had progressive leukemia.

    Formulation Used May Be Suspect

    Westervelt points out that problems in their trial may have been with the formulation of arsenic trioxide that they used.

    "Our observations should nonetheless raise a cautionary flag to practitioners regarding the potential for previously under-appreciated cardiac toxicity with this agent," Westervelt says.

    Genetics May Play a Role

    The researchers also report that genetics may play a role in the effects of arsenic trioxide: "The fact that all three patients who died early in our study were of African American descent raises the possibility of a genetic basis for differing susceptibilities to arsenic trioxide toxicity between individual patients."

    According to the researchers, this study and other anecdotal evidence of "serious potentially arsenic-related cardiac toxicity presented here suggest that this agent, at the doses currently used for the treatment of APL, may have more significant toxicity than previously recognized."

    Herman Kattlove, MD, a medical oncologist with the American Cancer Society (ACS) suggests that if a patient failed all other treatment, then this is still their best hope prior to a bone marrow transplant.

    But he says, "I would not recommend taking it as first-line therapy until the cause of these deaths have been worked out."

    Kattlove says he thinks the main issue raised is whether the formulation used in this study had any safety problems, because other studies of this drug with different formulations did not report any adverse effects.

    "But," Kattlove adds, "although earlier studies with the standard formulation did not lead to sudden deaths, arsenic is known to cause heart beat abnormalities and patients receiving this drug will need careful monitoring."

Share this